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Abstract 
Background: A recently developed prediction score based on age, arterial oxygen partial pressure to fractional 
inspired oxygen ratio (PaO2/FiO2) and plateau pressure (abbreviated as ‘APPS’) was shown to accurately predict mor-
tality in patients diagnosed with the acute respiratory distress syndrome (ARDS). After thorough temporal external 
validation of the APPS, we tested the spatial external validity in a cohort of ARDS patients recruited during 3 years in 
two hospitals in the Netherlands.
Methods: Consecutive patients with moderate or severe ARDS according to the Berlin definition were included in 
this observational multicenter cohort study from the mixed medical-surgical ICUs of two university hospitals. The 
APPS was calculated per patient with the maximal airway pressure instead of the plateau pressure as all patients were 
ventilated in pressure-controlled mode. The predictive accuracy for hospital mortality was evaluated by calculating 
the area under the receiver operating characteristics curve (AUC-ROC). Additionally, the score was recalibrated and 
reassessed.
Results: In total, 439 patients with moderate or severe ARDS were analyzed. All-cause hospital mortality was 43 %. 
The APPS predicted all-cause hospital mortality with moderate accuracy, with an AUC-ROC of 0.62 [95 % confidence 
interval (CI) 0.56–0.67]. Calibration was moderate using the original cutoff values (Hosmer–Lemeshow goodness of 
fit P < 0.001), and recalibration was performed for the cutoff value for age and plateau pressure. This resulted in good 
calibration (P = 1.0), but predictive accuracy did not improve (AUC-ROC 0.63, 95 % CI 0.58–0.68).
Conclusions: The predictive accuracy for all-cause hospital mortality of the APPS was moderate, also after recalibra-
tion of the score, and thus the APPS does not seem to be fitted for that purpose. The APPS might serve as simple tool 
for stratification of mortality in patients with moderate or severe ARDS. Without recalibrations, the performance of the 
APPS was moderate and we should therefore hesitate to blindly apply the score to other cohorts of ARDS patients.
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Background
Outcome prediction in critically ill patients is commonly 
performed using general-purpose scoring systems such 
as the Acute Physiology and Chronic Health Evaluation 
(APACHE) score [1] and the Simplified Acute Physiology 
Score (SAPS) [2], which have been developed in unse-
lected series of ICU patients. Other scoring systems have 
been developed for selective patient groups in the inten-
sive care unit (ICU), e.g., for patients who develop acute 
kidney injury [3, 4] and liver failure [5].
Unfortunately, no such prediction system has been 
developed for patients with the acute respiratory distress 
syndrome (ARDS). Outcome prediction in patients with 
ARDS based on PaO2/FiO2, as proposed in the Ameri-
can-European Consensus Conference (AECC) criteria [6] 
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and the Berlin definition for ARDS [7], does neither show 
good predictive accuracy nor show calibration [7–9]. 
Very recently, a scoring system was developed that pre-
dicts hospital mortality with good accuracy in patients 
with ARDS [10]. This score is based on three routinely 
available variables: age, the arterial oxygen partial pres-
sure to fractional inspired oxygen ratio (PaO2/FiO2) and 
plateau pressure measured 24 h after the initial diagno-
sis of ARDS, and was thus coined the APPS. However, 
after excellent results of temporal external validation of 
this so-called APPS by the original authors, spatial exter-
nal validation (e.g., the accuracy of prediction in another 
location) is highly needed.
Therefore, we tested the predictive accuracy and 
calibration of the APPS in a cohort of consecutive pro-
spectively identified ARDS patients in two university 
hospitals in the Netherlands and recalibrated the score 
for our population of patients. We hypothesized that the 
ability of the APPS to predict hospital mortality remains 
excellent after spatial external validation.
Methods
Study design
The patient cohort was previously described by Gebo-
ers et al. [11]. Patients with ARDS, according to the Ber-
lin definition, were selected from the parent ‘Molecular 
Diagnosis and Risk Stratification’ (MARS) study, per-
formed in the ICUs of two tertiary care hospitals in the 
Netherlands (Academic Medical Center, Amsterdam, 
The Netherlands; University Medical Center, Utrecht, 
The Netherlands). The Medical Ethics Committees of 
both hospitals approved the study protocol and opt-out 
consent method. The patient or their legal representative 
was presented with a brochure and opt-out form, to be 
completed in case of unwillingness to participate.
Setting
ICUs are closed-format units, with a team of board-certi-
fied critical care physicians, fellows in critical care medi-
cine and board-certified ICU nurses caring for a mixed 
medical-surgical population of patients. The nurse-to-
patient ratio was from 1:1 to 1:2. Patients received lung-
protective mechanical ventilation per protocol, which 
mandated the use of low tidal volumes (6–8 mL/kg pre-
dicted body weight), a minimum level of positive end-
expiratory pressure of 5  cmH2O, which together with 
FiO2 was titrated based on frequent PaO2 measurements. 
As part of standard care, nurses and attending physicians 
checked hourly whether there were signs of spontane-
ous breathing activity by comparing the set and meas-
ured respiratory rate and by observing flow curves at the 
ventilator. In case this was seen, the ventilator could be 
switched to an assisted ventilation mode, or additional 
sedation was given. Recruitment maneuvers and prone 
ventilation were used early and frequently if hypox-
emia did not respond to higher levels of PEEP and FiO2. 
Details of the ventilation protocol were reported before 
[12]. A conservative fluid strategy was followed accord-
ing to the ARDSnet protocol [13], and analgo-sedation 
was applied using sedation scales and bolus sedation with 
midazolam or continuous sedation with propofol. Details 
of the analgo-sedation protocol were also reported before 
[14]. Neuromuscular blocking agents were not routinely 
used, and if used only as a bolus.
Inclusion and exclusion criteria
Consecutive adult patients admitted to the ICU with an 
expected length of stay of more than 24 h from January 
2011 to December 2013 were eligible for participation in 
the MARS study. ARDS was defined according to the cri-
teria stated by the American-European Consensus Con-
ference on ARDS: i.e., the diagnosis required an acute 
onset of symptoms, the presence of bilateral infiltrates 
on chest radiography, a pulmonary-artery wedge pres-
sure <18 mmHg and/or the absence of signs of left ven-
tricular dysfunction, and a PaO2/FiO2 ≤  200. Although 
our study started in 2011, before the recent ‘Berlin defi-
nition for ARDS’, we found that 100  % patients would 
have fulfilled the criteria of the new definition. Patients 
that were discharged or transferred to another ICU 
within 24 h after the diagnosis of ARDS were excluded 
from the present analysis, as they could not be used to 
validate the results reported by the ALIEN Network 
investigators. There were no additional inclusion or 
exclusion criteria for the present analysis. ARDS was 
diagnosed by a dedicated team of researchers who were 
trained in the proper use of the AECC criteria for ARDS 
[12]. The cause for ARDS was determined and scored in 
the following categories: pneumonia, aspiration, other 
pulmonary (i.e., inhalation trauma, near drowning), sep-
sis, trauma or major surgery, pancreatitis or other non-
pulmonary (i.e., blood transfusion, toxic medication). In 
the event of multiple causes for ARDS, each cause was 
scored separately.
APPS
The APPS was calculated as proposed in the original 
publication [10]. However, instead of plateau pressure, 
maximal airway pressure was used since pressure-con-
trolled ventilation was used exclusively in our setting. 
The maximal airway pressure during pressure-controlled 
ventilation is equal to the plateau pressure during vol-
ume-controlled ventilation under most circumstances. 
As described above, nurses and physicians screened 
whether the ventilator could be switched to an assisted 
ventilation mode.
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Outcomes
All-cause in-hospital mortality was used as the primary 
endpoint. The data collectors were blind for this outcome 
at the moment of data collection as the all parameters 
were collected prospectively. If a patient was transferred 
to another hospital, that hospital was contacted to obtain 
the date of hospital discharge. Follow-up was complete 
for all patients.
Statistical analysis
Data were expressed as mean ± SD, median with inter-
quartile range or number with percentage, as appropri-
ate. Differences between groups were tested with the 
Pearson Chi-square or Fisher exact test for categorical 
variables and with T test, one-way ANOVA, Mann–
Whitney or Kruskal–Wallis test for numerical variables. 
A P value below 0.05 was considered significant. All anal-
yses were performed in R via the R-studio interface.
The predictive performance of the APPS was assessed 
by quantifying the calibration and the accuracy of the 
score [15]. The predictive accuracy was expressed in the 
area under the receiver operating characteristics curve 
(AUC-ROC), and the predictive accuracy of the APPS 
was compared to the APACHE IV score. Sensitivity, 
specificity and likelihood ratios were calculated for the 
optimal cutoff obtained by the Youden index. A Kaplan–
Meier curve was constructed for the APPS categories 
3–4, 5–7, 8–9, as in the original report on the APPS [10]. 
Calibration was visualized by plotting the APPS against 
the percentage of non-survivors at that score and quan-
tified by the Hosmer–Lemeshow goodness-of-fit test. 
Recalibration was performed manually, and measures 
of calibration and predictive accuracy were reassessed. 
A sensitivity analysis was performed in patients that 
received mechanical ventilation according to the ventila-
tion protocol in the derivation study for the APPS (i.e., 
patients were ventilated using the following settings: 
PEEP ≥  10 cmH2O and FiO2 ≥  50 %). A P value below 
0.05 was considered significant. All analyses were per-
formed in R via the R-studio interface.
Results
The cohort consisted of 439 patients with moderate or 
severe ARDS. Baseline characteristics are described in 
Table  1. Pressure-controlled ventilation was exclusively 
used; indeed, volume-controlled ventilation and assisted 
ventilation modes were not used at the moments data 
were collected for the present investigation. All-cause 
hospital mortality was 43  %. The mean APPS was 5 in 
surviving patients and 6 in non-surviving patients (Addi-
tional file  1: Figure E1; P  <  0.001). The APPS predicted 
all-cause hospital mortality with moderate accuracy 
with an AUC-ROC of 0.62 (95  % confidence interval 
0.56–0.67, see Fig. 1; Table 2), which was not significantly 
different from the predictive value of the APACHE IV 
score (AUC-ROC 0.66, 95 % CI 0.61–0.71; P = 0.22). The 
APPS showed a disturbed calibration at a score of 4–5 
(Fig. 1; P < 0.001). This was mainly due to the categoriza-
tion of the variables age and Pmax (Table  3, Additional 
file  1: Figure E2). This was translated into overlapping 
Kaplan–Meier curves for the APPS categories 3–4 and 
5–7 (Additional file 1: Figure E3).
Recalibration was performed for two of the three facets 
of the APPS. The age limit for 2 points was set to 47 and 
for 3 points to above 59 years (see Table 4). A maximum 
airway pressure above 30 resulted in 2 points and above 
33 in 3 points. This resulted in good calibration (Fig. 1; 
Table 4; Additional file 1: Figure E4, E5, P = 1.0), but pre-
dictive accuracy remained moderate (AUC-ROC 0.63, 
95 % CI 0.58–0.68, Fig. 1). Survival was significantly dif-
ferent when the APPS categories were changed to 3, 4–7 
and 8–9 (P < 0.001, Additional file 1: Figure E6).
A sensitivity analysis was limited to patients that were 
ventilated following the protocol that was used in the 
derivation cohort (N =  151), where the ventilation data 
were collected under the following standardized ventila-
tory settings: PEEP ≥ 10 cmH2O and FiO2 ≥ 50 %. This 
analysis confirmed a moderate predictive accuracy for 
the original (AUC-ROC 0.62, 95 % CI 0.54–0.71) and the 
recalibrated APPS (AUC-ROC 0.64, 95 % CI 0.55–0.73).
Discussion
Spatial external validation of the APPS in two university 
hospitals in the Netherlands showed a considerable lower 
predictive accuracy for all-cause hospital mortality than 
in the derivation and temporal validation population in 
the Spanish hospitals. Calibration was also disturbed, but 
this was resolved after minor modification of the score.
Patient characteristics were strikingly similar in both 
studies. For example, hospital mortality was compara-
ble between the cohorts (46 % in the derivation cohort, 
42  % in temporal validation cohort and 43  % in spatial 
validation cohort). Furthermore, ventilator parameters 
were also comparable, with the exception of FiO2 (80 % 
in derivation and temporal validation cohorts, 60  % in 
spatial validation cohort). Additionally, the strength of 
the association between aspects of the APPS and mor-
tality, as exemplified by the odds ratio (Tables 2, 3), was 
similar between the cohorts. Importantly, the odds ratio 
is a measure of effect size and not of discrimination. This 
implies that the association between hospital mortality 
and age, PaO2/FiO2 and plateau pressure was very similar 
between the cohorts, but that this did not result in suffi-
cient discrimination in the population we included.
Any difference in patient selection, practice or data 
collection between the temporal validation and spatial 
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validation cohorts may explain the differences in discrimi-
nation. First, it could be argued that differences arose 
because we used the maximal airway pressure instead of 
the plateau pressure. Although the maximal airway pres-
sure can be used to approximate the plateau pressure in 
theory [16], it could be that, for example, during undetected 
spontaneous breathing effort these values were influenced 
[17]. In our setting, however, nurses and physicians care-
fully and hourly check whether a patient is breathing spon-
taneously. If so, the local ventilation protocol dictates the 
use of an assisted ventilation mode, and this was not seen at 
the moments of data collection for this study. The maximal 
airway pressure and the plateau pressure are both surrogate 
measures for alveolar distending pressure, and the accuracy 
of the score may improve if that pressure would be meas-
ured directly. PaO2/FiO2 may be influenced by ventilator 
settings [8], and therefore we performed a sensitivity analy-
ses for patients that were using the standardized ventilator 
settings (PEEP ≥ 10 cmH2O and FiO2 ≥ 50 %) that were 
used in the original study. However, this did not change the 
results. This implies that differences in ventilation strat-
egies are not likely to have caused the lower predictive 
accuracy. Thus, the APPS may have been over-fitted to the 
setting in which it is developed and validation. This obser-
vation is further supported by the observation that not only 
maximal airway pressure and PaO2/FiO2 discriminated dif-
ferently between the cohorts, but that this lower accuracy 
was also found for age. In contrast to the former, data col-
lection will not influence the age of the patient. Thereby, we 
can establish that the lower accuracy may partly be due to 
differences in data collection, but also that the APPS can-
not be generalized to other populations due to over-fitting 
to the derivation population.
The presented data suggest that calibration of the 
APPS is sufficiently good after slight modification of the 
original score. Calibration may be more important than 
predictive accuracy for some purposes. For example, for 
inclusion into clinical trials the added value of discrimi-
nation is limited, while calibration is pivotal. A well-
calibrated score could lead to the inclusion of a patient 
population with the mortality to which the study is pow-
ered (prognostic enrichment), something that has been 
an issue in many investigational trials [18–20]. However, 
it is worrisome that recalibration of the cutoffs for age 
and pressure was needed as this limits the implementa-
tion of the score in new clinical environments. Additional 
Table 1 Baseline characteristics of 439 survivors and non-survivors with the acute respiratory distress syndrome in the 
Netherlands
Survivors (N = 252) Non-survivors (N = 187; 43 %) P
Gender, male, N (%) 163 (64.7) 120 (64.2) 0.92
Age, mean ± SD 58.5 ± 15.4 63.1 ± 12.7 0.001
Cause of ARDS, N (%)
 Pneumonia 154 (61.1) 115 (61.5) 1.0
 Aspiration 25 (9.9) 16 (8.6) 0.76
 Other pulmonary 2 (0.8) 1 (0.5) 1.0
 Sepsis 144 (57.1) 132 (70.6) 0.003
 Trauma 38 (15.1) 15 (8.0) 0.029
 Pancreatitis 2 (0.8) 6 (3.2) 0.069
 Other non-pulmonary 29 (11.5) 17 (9.1) 0.43
Disease severity, mean ± SD
 APACHE IV 85.5 ± 27 102.7 ± 30.7 <0.001
 SOFA score 8.6 ± 3.2 10.1 ± 4.1 <0.001
Physiological parameters, mean ± SD
 pH, median ± IQR 7.4, 7.4–7.5 7.4, 7.3–7.4 0.001
 PaCO2 42.1 ± 9 44.4 ± 12.1 0.039
 PaO2/FiO2 126.8 ± 38.3 127.7 ± 43.1 0.81
 Respiratory system compliance 28.9 ± 15.6 37.4 ± 20.9 <0.001
Ventilation parameters, mean ± SD
 Tidal volume (ml/kg PBW) 7.7 ± 2 7.5 ± 1.7 0.38
 FiO2 53.2 ± 12.9 56.7 ± 16.7 0.017
 Respiratory rate 22 ± 7 25 ± 8 <0.001
 PEEP (cmH2O) 10.4 ± 3.6 10.9 ± 4 0.2
 Pmax (cmH2O) 26.2 ± 7.9 28.2 ± 9.4 0.018
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validation attempts could further clarify the optimal cut-
offs for the score and may allow for stratification of newly 
recruited ARDS patients.
Based on our data, the validity of the APPS as a predic-
tion score for mortality in ARDS is disputable. But what 
purpose would a prediction score for mortality serve? 
The authors that proposed the APPS suggest that the 
score may be used to identify patients in whom benefit 
from the treatment may be limited. However, here the 
same point can be made as in the previous paragraph; 
it may be sufficient to identify groups of patients that 
have a higher or lower mortality and treat those groups 
differently. A well-calibrated score will serve this point, 
and for that purpose, the APPS may still qualify. It could 
be argued that we should have improved the prediction 
score. However, this was not the aim of this study. Thor-
ough validation of well-developed scores is more impor-
tant than development of multiple prediction tools [21]. 
Fig. 1 Calibration and predictive accuracy of the APPS for hospital mortality. a Original APPS. b Recalibrated APPS. c ROC curves. Each bar repre-
sents the percentage of patients that did not survive that hospital admission. The number indicates the total number of patients with that APPS
Table 2 Test characteristics
ROC receiver operating characteristics curve, CI 95 % confidence interval of area under the ROC curve, Sens sensitivity, Spec specificity, LR likelihood ratio
ROC CI Cutoff Sens Spec LR+ LR−
Complete cohort (N = 439)
 APPS 0.62 0.56–0.67 5.5 0.63 0.56 1.43 0.66
 Recalibrated APPS 0.63 0.58–0.68 5.5 0.63 0.56 1.43 0.66
Sensitivity analysis (N = 151)
 APPS 0.62 0.54–0.71 5.5 0.38 0.85 2.53 0.73
 Recalibrated APPS 0.64 0.55–0.73 5.5 0.48 0.78 2.18 0.37
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The two-center, single national design is another limita-
tion of the present study as ideally the accuracy of a pre-
dictive test such as the APPS is validated in a prospective, 
international observational cohort study.
To conclude, our data suggest the APPS could serve as 
simple tool for stratification of mortality in patients with 
moderate or severe ARDS. Importantly, without recali-
brations the performance of the APPS was moderate and 
we should therefore hesitate to blindly apply the score to 
new series of patients. The predictive accuracy for all-
cause hospital mortality was moderate, also after recali-
bration of the score, and thus the APPS does not seem to 
be fitted for that purpose.
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